|
Pancreatic lesions (n = 73)
|
n (%)
|
| Adenocarcinoma |
42 (57.5) |
| Pancreatic neuroendocrine tumor |
9 (12.3) |
| Metastatic adenocarcinoma |
9 (12.3) |
| Benign lymphoid cells (reactive LN) |
6 (8.2) |
| Abscess |
1 (1.4) |
| Chronic pancreatitis |
1 (1.4) |
| Leiomyoma |
1 (1.4) |
| Non-diagnostic |
4 (5.5) |
|
Non-pancreatic lesions (n = 67)
|
n (%)
|
| Benign lymphoid cells (reactive LN) |
14 (20.9) |
| GIST |
12 (17.9) |
| B-cell Lymphoma |
6 (9.0) |
| Adenocarcinoma |
|
| Metastatic adenocarcinoma of unknown primary |
7 (10.5) |
| Metastatic pancreas adenocarcinoma |
4 (6.0) |
| Lung adenocarcinoma |
3 (4.5) |
| Gallbladder adenocarcinoma |
1 (1.5) |
| Metastatic colon adenocarcinoma |
1 (1.5) |
| Metastatic breast adenocarcinoma |
1 (1.5) |
| Leiomyoma/leiomyomasacroma |
3 (4.5) |
| Hepatocellular carcinoma |
2 (3.0) |
| Myxoid tumor |
1 (1.5) |
| Paraganglioma |
1 (1.5) |
| Abscess |
1 (1.5) |
| Pseudopapillary tumor |
1 (1.5) |
| Non-diagnostic |
9 (13.4) |
